Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to $1.5 million.

  • Ensysce Biosciences' Cash from Financing Activities fell 6486.13% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 5825.52%. This contributed to the annual value of $9.9 million for FY2024, which is 1285.18% up from last year.
  • Latest data reveals that Ensysce Biosciences reported Cash from Financing Activities of $1.5 million as of Q3 2025, which was down 6486.13% from $1.9 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Cash from Financing Activities registered a high of $9.2 million during Q4 2021, and its lowest value of -$391270.0 during Q1 2022.
  • In the last 5 years, Ensysce Biosciences' Cash from Financing Activities had a median value of $1.9 million in 2025 and averaged $2.8 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 16384.31% in 2022, then soared by 413169.88% in 2024.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Cash from Financing Activities stood at $9.2 million in 2021, then plummeted by 78.88% to $1.9 million in 2022, then decreased by 24.7% to $1.5 million in 2023, then tumbled by 92.3% to $112575.0 in 2024, then skyrocketed by 1189.33% to $1.5 million in 2025.
  • Its Cash from Financing Activities was $1.5 million in Q3 2025, compared to $1.9 million in Q2 2025 and $1.3 million in Q1 2025.